VCVanessa M. Cowton

Vanessa M. Cowton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vanessa M. Cowton has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SARS-CoV-2 envelope protein induces LC3 lipidation via the V-ATPase-ATG16L1 axis

    by Carmen Figueras-Novoa, Lewis Timimi, Elena Marcassa, Raquel Taveira-Marques, Lorin Adams, Ming Jiang, Mary Wu, Beatriz Montaner, Kevin Ng, Giuditta De Lorenzo, et al.

    Coronaviruses encode envelope (E), a structural component of the virion that is important for assembly and egress. E has proton channel activity that prevents premature rearrangement of the spike glycoprotein as virions encounter acidic compartments as they exit the cell. How infected cells respond to this pH disruption during coronavirus infection is unknown. Here we show that SARS-CoV-2 E ion channel activity triggers the proton pump V-ATPases to recruit the ATG16L1 complex during infection. This results in ATG8 molecules such as LC3B decorating perturbed compartments. This recruitment of autophagy machinery does not inhibit viral replication, rather SARS-CoV-2 exploits this response. Inhibition of the V-ATPase/ATG16L1 interaction using the Salmonella effector SopF inhibits SARS-CoV-2 replication. Careful distinction between use of the autophagic machinery from canonical macroautophagy is required in order to better understand coronavirus replication and for rational targeting of any potential host-directed therapies.


  • Open Access

    Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic

    by Wilhelm Furnon, Vanessa M. Cowton, Giuditta De Lorenzo, Richard Orton, Vanessa Herder, Diego Cantoni, Georgios Ilia, Diogo Correa Mendonca, Karen Kerr, Jay Allan, et al.

    SARS-CoV-2 variants are mainly defined by mutations in their spike. It is therefore critical to understand how the evolutionary trajectories of spike affect virus phenotypes. So far, it has been challenging to comprehensively compare the many spikes that emerged during the pandemic in a single experimental platform. Here we generated a panel of recombinant viruses carrying different spike proteins from 27 variants circulating between 2020 and 2024 in the same genomic background. We then assessed several of their phenotypic traits both in vitro and in vivo. We found distinct phenotypic trajectories of spike among and between variants circulating before and after the emergence of Omicron variants. Spike of post-Omicron variants maintained enhanced tropism for the nasal epithelium and large airways but displayed, over time, several phenotypic traits typical of the pre-Omicron variants. Hence, spike with phenotypic features of both pre- and post-Omicron variants may continue to emerge in the future.


  • Open Access

    Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic

    by Wilhelm Furnon, Vanessa Cowton, Giuditta De Lorenzo, Richard Orton, Vanessa Herder, Diego Cantoni, Georgios Ilia, Diogo Correa Mendonca, Karen Kerr, Jay Allan, et al.

    Variants of SARS-CoV-2, defined mainly by mutations in the spike glycoprotein, have emerged throughout the COVID-19 pandemic and will undoubtedly continue to emerge in the future. Spike strongly influences virus phenotype, and it is therefore critical to understand the evolution of this viral protein during distinct phases of the pandemic. Here, we generated a panel of recombinant viruses carrying spike from 27 of the most significant variants, circulating between 2020 and 2024, within an otherwise identical genomic backbone. We systematically assessed phenotypic traits of these viruses both in vitro and in vivo in hamsters. Overall, we determined distinct phenotypic trajectories of spike among and between the variants circulating before (“pre-Omicron") and after (“post-Omicron”) the emergence of Omicron. Spillover of SARS-CoV-2 in the human population was followed by a period of adaptation and fine-tuning to the host in the pre-Omicron variants. Omicron simultaneously “reset” several established phenotypes of previously circulating variants. Since then, spike of post-Omicron variants maintained its enhanced tropism for the nasal epithelium but displayed over time several phenotypic traits typical of the pre-Omicron variants. These data suggest that it may be possible for spike with phenotypic features of both pre- and post-Omicron variants to emerge in the future.


  • Top Cited Papers
    Open Access

    Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants

    by Ann-Kathrin Reuschl, Lucy G. Thorne, Matthew V. X. Whelan, Roberta Ragazzini, Wilhelm Furnon, Vanessa M. Cowton, Giuditta De Lorenzo, Dejan Mesner, Jane L. E. Turner, Giulia Dowgier, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human adaptation resulted in distinct lineages with enhanced transmissibility called variants of concern (VOCs). Omicron is the first VOC to evolve distinct globally dominant subvariants. Here we compared their replication in human cell lines and primary airway cultures and measured host responses to infection. We discovered that subvariants BA.4 and BA.5 have improved their suppression of innate immunity when compared with earlier subvariants BA.1 and BA.2. Similarly, more recent subvariants (BA.2.75 and XBB lineages) also triggered reduced innate immune activation. This correlated with increased expression of viral innate antagonists Orf6 and nucleocapsid, reminiscent of VOCs Alpha to Delta. Increased Orf6 levels suppressed host innate responses to infection by decreasing IRF3 and STAT1 signalling measured by transcription factor phosphorylation and nuclear translocation. Our data suggest that convergent evolution of enhanced innate immune antagonist expression is a common pathway of human adaptation and link Omicron subvariant dominance to improved innate immune evasion.


  • Open Access

    Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

    by Brian J. Willett, Joe Grove, Oscar A. MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan, Shirin Ashraf, et al.


  • Top Cited Papers
    Open Access

    SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

    by Brian J. Willett, Joe Grove, Oscar A. MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan, Shirin Ashraf, et al.

    Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.


  • Open Access

    The Neutralizing Antibody Responses of Individuals That Spontaneously Resolve Hepatitis C Virus Infection

    by Vanessa M. Cowton, James I. Dunlop, Sarah J. Cole, Rachael E. Swann, Arvind H. Patel

    Hepatitis C virus (HCV) infection is a major global health problem. In the majority of cases the virus is not cleared by the host immune response and progresses to chronic infection. Studies of the neutralizing antibody responses in individuals that naturally clear infection are limited. Understanding what constitutes a successful antibody response versus one that has ‘failed’ and resulted in chronic infection is important to understand what type of antibody response would need to be elicited by a protective vaccine. Samples from spontaneous clearers are difficult to obtain therefore studies are often limited. In our study through HCV Research UK, we had access to a cohort of over 200 samples. We identified the samples that contained HCV neutralizing antibodies using ELISA and HCV pseudoparticle (HCVpp) assays. We then utilised mutagenesis and cross-competition analysis to determine the profile of the neutralizing antibody responses. In addition, we analysed a cohort of samples from chronic infection using the same techniques to enable direct comparison of the antibody profiles observed in both cohorts. We conclude that similar profiles are present in both cohorts indicating that it is not the neutralizing antibody response per se that determines the outcome of infection. These data will provide useful information for future HCV vaccine design.


  • Top Cited Papers
    Open Access

    The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein

    by Thomas P. Peacock, Jonathan C. Brown, Jie Zhou, Nazia Thakur, Ksenia Sukhova, Joseph Newman, Ruthiran Kugathasan, Ada W.C. Yan, Wilhelm Furnon, Giuditta De Lorenzo, et al.

    The SARS-CoV-2 Omicron/BA.1 lineage emerged in late 2021 and rapidly displaced the Delta variant before being overtaken itself globally by, the Omicron/BA.2 lineage in early 2022. Here, we describe how Omicron BA.1 and BA.2 show a lower severity phenotype in a hamster model of pathogenicity which maps specifically to the spike gene. We further show that Omicron is attenuated in a lung cell line but replicates more rapidly, albeit to lower peak titres, in human primary nasal cells. This replication phenotype also maps to the spike gene. Omicron spike (including the emerging Omicron lineage BA.4) shows attenuated fusogenicity and a preference for cell entry via the endosomal route. We map the altered Omicron spike entry route and partially map the lower fusogenicity to the S2 domain, particularly the substitution N969K. Finally, we show that pseudovirus with Omicron spike, engineered in the S2 domain to confer a more Delta-like cell entry route retains the antigenic properties of Omicron. This shows a distinct separation between the genetic determinants of these two key Omicron phenotypes, raising the concerning possibility that future variants with large antigenic distance from currently circulating and vaccine strains will not necessarily display the lower intrinsic severity seen during Omicron infection.


  • Open Access

    Mutations that adapt SARS-CoV-2 to mustelid hosts do not increase fitness in the human airway.

    by Jie Zhou, Thomas Peacock, Jonathan Brown, Daniel Goldhill, Ahmed Elrefaey, Rebekah Penrice-Randal, Vanessa Cowton, Giuditta De Lorenzo, Wilhelm Furnon, William Harvey, et al.

    SARS-CoV-2 has a broad mammalian species tropism infecting humans, cats, dogs and farmed mink. Since the start of the 2019 pandemic several reverse zoonotic outbreaks of SARS-CoV-2 have occurred in mink, one of which reinfected humans and caused a cluster of infections in Denmark. Here we investigate the molecular basis of mink and ferret adaptation and demonstrate the spike mutations Y453F, F486L, and N501T all specifically adapt SARS-CoV-2 to use mustelid ACE2. Furthermore, we risk assess these mutations and conclude mink-adapted viruses are unlikely to pose an increased threat to humans, as Y453F attenuates the virus replication in human cells and all 3 mink-adaptations have minimal antigenic impact. Finally, we show that certain SARS-CoV-2 variants emerging from circulation in humans may naturally have a greater propensity to infect mustelid hosts and therefore these species should continue to be surveyed for reverse zoonotic infections.


  • Open Access

    Mutations that adapt SARS-CoV-2 to mustelid hosts do not increase fitness in the human airway

    by Jie Zhou, Thomas P. Peacock, Jonathan C. Brown, Daniel H. Goldhill, Ahmed M.E. Elrefaey, Rebekah Penrice-Randal, Vanessa M. Cowton, Giuditta De Lorenzo, Wilhelm Furnon, William T. Harvey, et al.

    SARS-CoV-2 has a broad mammalian species tropism infecting humans, cats, dogs and farmed mink. Since the start of the 2019 pandemic several reverse zoonotic outbreaks of SARS-CoV-2 have occurred in mink, one of which reinfected humans and caused a cluster of infections in Denmark. Here we investigate the molecular basis of mink and ferret adaptation and demonstrate the spike mutations Y453F, F486L, and N501T all specifically adapt SARS-CoV-2 to use mustelid ACE2. Furthermore, we risk assess these mutations and conclude mink-adapted viruses are unlikely to pose an increased threat to humans, as Y453F attenuates the virus replication in human cells and all 3 mink-adaptations have minimal antigenic impact. Finally, we show that certain SARS-CoV-2 variants emerging from circulation in humans may naturally have a greater propensity to infect mustelid hosts and therefore these species should continue to be surveyed for reverse zoonotic infections.